Changes in predictive capacity when adding Ticagrelor and Clopidogrel to an existing allogeneic bloodtransfuion prediction model for cardiac surgery.
Recruiting
- Conditions
- Coronary heart disease, valvular disease, vascular disease
- Registration Number
- NL-OMON22097
- Lead Sponsor
- Department of Cardiac Surgery and Department of Anesthesia Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 3500
Inclusion Criteria
•Patients > 18 years
•Patients receiving on-pump cardiac surgery.
•Patients receiving off-pump cardiac surgery.
Exclusion Criteria
A potential patient who meets any of the following criteria will be excluded from participation in the data collection:
•Cardiac surgery for congenital disorders
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method How accurately does the TRACK model predict allogeneic blood transfusions in the Amsterdam UMC, location AMC, cardiothoracic surgery population?
- Secondary Outcome Measures
Name Time Method 1.How does the predictive capacity of the TRACK model change when the pre-operative use of P2Y12 inhibitors are added as a predictive factor?<br>2.What is the relationship between pre-operative P2Y12 use and amount and type of blood product transfused<br>3. Is there a difference in the use of transfusion products between Ticagrelor and other P2Y12 inhibitors, such as Clopidogrel?<br>4.Is there a difference in length of hospital stay, and the 30/90 day mortality in patients using Ticagrelor, when compared to other P2Y12 inhibitors such as Clopidogrel?<br>